Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
-
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
-
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ContraFect (CFRX) Prices 10M Share Common Offering at $5/Sh
-
ContraFect Corporation Prices Public Offering of Common Stock
-
ContraFect (CFRX) Prices 11.797M Share & Warrants Offering at $4.90/Sh
-
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
-
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference
-
ContraFect Corp. (CFRX) PT Raised to $22 at Maxim Group
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock
-
ContraFect (CFRX) Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
-
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
-
ContraFect (CFRX) Announces Proposed Common Share Offering & Concurrent Private Placement of Common Share to Pfizer Inc. (PFE)
-
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.
-
Maxim Group Starts ContraFect Corp. (CFRX) at Buy
-
Maxim Group Assumes ContraFect Corp. (CFRX) at Buy
-
Maxim Group Maintains Hold Rating on ContraFect (CFRX); New CF-301 Data to be Presented at ECCMID
-
ContraFect (CFRX) PT Trimmed to $7 at Maxim Group as Results Awaited
-
ContraFect (CFRX) PT Cut to $9 at Maxim Group; 'Buy' Maintained

